KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbbVie (ABBV) EBITDA Margin (2016 - 2025)

AbbVie (ABBV) has disclosed EBITDA Margin for 14 consecutive years, with 27.34% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 3721.0% to 27.34% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 24.65% through Dec 2025, up 843.0% year-over-year, with the annual reading at 24.65% for FY2025, 843.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 27.34% at AbbVie, up from 12.07% in the prior quarter.
  • The five-year high for EBITDA Margin was 36.39% in Q4 2022, with the low at 9.87% in Q4 2024.
  • Average EBITDA Margin over 5 years is 25.62%, with a median of 27.81% recorded in 2024.
  • The sharpest move saw EBITDA Margin tumbled -3221bps in 2024, then surged 3721bps in 2025.
  • Over 5 years, EBITDA Margin stood at 34.09% in 2021, then grew by 7bps to 36.39% in 2022, then plummeted by -39bps to 22.34% in 2023, then tumbled by -144bps to 9.87% in 2024, then skyrocketed by 377bps to 27.34% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 27.34%, 12.07%, and 31.73% for Q4 2025, Q3 2025, and Q2 2025 respectively.